Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

Allergic Conjunctivitis Clinical Trial

Official title:

A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01443442
• Other study ID #: MAC-06-11
• Status: Completed
• Phase: Phase 4
• Start date: October 2011
• Est. completion date: December 2012

Study information

• Verified date: July 2019
• Source: Southern California College of Optometry
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically, patients manifest symptoms in the spring, summer and fall, when airborne allergens are at their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and burning.

This is a randomized clinical study to evaluate the efficacy of Bepreve® (bepotastine besilate 1.5% ophthalmic solution) compared to Alrex® (loteprednol etabonate 0.2%) in the treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years. The study will be a two-week study with four visits. Ocular signs (eye redness( and symptoms (itching) will be monitored as outcome variables.

Description:

Investigator and Study Center:

Judy Tong, OD Eye Care Center Southern California College of Optometry

Test Product, Dose and Mode of Administration:

Bepreve (bepotastine besilate ophthalmic solution) 1.5% bid ou vs. Alrex (loteprednol etabonate ophthalmic suspension) 0.2% qid ou

Study Title:

A Single-Center, Masked, Randomized Study Comparing Bepreve (bepotastine besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (loteprednol etabonate) 0.2% - Corticosteroid in Subjects with Moderate to Severe Allergic Conjunctivitis

Primary Objective(s):

The primary objective of this study is to compare the efficacy of Bepreve (bepotastine besilate) 1.5% ophthalmic solution compared to Alrex (loteprednol etabonate) 0.2% in the treatment of moderate to severe allergic conjunctivitis in patients over the age of 18 years of age

Study Design:

Interventional, Randomized, Parallel Arm, Investigator Masked

Study Population:

Subjects over the age of 18 years of age with moderate to severe allergic conjunctivitis.

Duration of Treatment: 14 days

Efficacy Assessments: Itching, Bulbar conjunctival injection, Bulbar conjunctival chemosis

Safety Assessments: N/A

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: December 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Moderate to severe allergic subjects (= 2.5 on a 0.0 to 4.0 itching scale AND

> grade 2.0 bulbar redness using validated (Efron) scale)

• Must be able to understand and sign an informed consent form that has been approved by the Institutional Review Board (IRB).

• Can comply with instillation of study drug

• Must be able to comply with the visit schedule and other requirements of the study.

Exclusion Criteria:

• Subjects who use daily wear (5-7 days / week, 6-16 hours/day)25 disposable soft hydrogel or silicone hydrogel contact lenses will be included in the study if they have been consistently wearing the same brand and have been using the same care solution for one month or longer. They will be asked to not wear their soft contact lenses to the eligibility visit (three days of no lens wear) and be willing to discontinue lens wear during the two weeks of the study because of the incompatibility of medicated eye drop instillation with contact lens wear and the potential confounding effect of contact lenses and care solutions.

• Active inflammation of the cornea, iris, anterior chamber

• Active or suspected herpetic eye disease (simplex, vaccinia, varicella)

• Active or suspected mycobacterial or acanthamoeba infection

• Active for suspected fungal disorders of the eye

• Persistent and significant dry eye syndrome

• Known allergy, contraindications or hypersensitivity to loteprednol, bepotastine, or its components

• Pregnancy or breast-feeding

• Use of topical eye drops, topical or systemic antihistamines, topical, nasal or systemic corticosteroids, immunosuppressive or immunomodulating agents, decongestants, aspirin, or non-steroidal antiinflammatory (NSAIDs) during the two weeks prior to the study.

• Participation in any other study within 30 days of this study.

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic

Intervention

Drug:
• bepotastine besilate, 1.5%
Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
• Loteprednol etabonate
Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days

Locations

Country	Name	City	State
United States	Eye Car Center, Southern California college of Optometry	Fullerton	California
United States	Eye Care Center, Southern Caalifornia College of Optometry	Fullerton	California

Sponsors (1)

Lead Sponsor	Collaborator
Southern California College of Optometry

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Ocular Itching at 14 Days	Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.	Change from Baseline in Ocular Itching at 14 Days